Journal article Open Access

DEVELOPMENT AND EVALUATION OF NANOEMULSION FOR IMPROVED ORAL DELIVERY OF LURASIDONE HYDROCHLORIDE.

B. Kusum*1, R. Shyamsunder2


DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:cnt="http://www.w3.org/2011/content#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://doi.org/10.5281/zenodo.2530509">
    <rdf:type rdf:resource="http://www.w3.org/ns/dcat#Dataset"/>
    <dct:type rdf:resource="http://purl.org/dc/dcmitype/Text"/>
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.5281/zenodo.2530509</dct:identifier>
    <foaf:page rdf:resource="https://doi.org/10.5281/zenodo.2530509"/>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>B. Kusum*1, R. Shyamsunder2</foaf:name>
        <foaf:givenName>R. Shyamsunder2</foaf:givenName>
        <foaf:familyName>B. Kusum*1</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>1Department of Pharmacy, University college of Technology, Osmania University, Telangana, INDIA. 2Head and Principal, University college of Technology, Osmania University, Telangana, INDIA.</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>DEVELOPMENT AND EVALUATION OF NANOEMULSION FOR IMPROVED ORAL DELIVERY OF LURASIDONE HYDROCHLORIDE.</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2018</dct:issued>
    <dcat:keyword>Oleic Acid, Propylene Glycol Dicaprate, Transcutol P, Propylene Glycol.</dcat:keyword>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2018-11-30</dct:issued>
    <owl:sameAs rdf:resource="https://zenodo.org/record/2530509"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/2530509</skos:notation>
      </adms:Identifier>
    </adms:identifier>
    <dct:isVersionOf rdf:resource="https://doi.org/10.5281/zenodo.2530508"/>
    <dct:isPartOf rdf:resource="https://zenodo.org/communities/iajpr"/>
    <dct:description>&lt;p&gt;Low aqueous solubility is a major problem faced during the formulation of NCE, Lurasidone Hydrochloride is an antipsychotic agent specially used in the treatment of schizophrenia. Lurasidone is practically insoluble in purified water, has poor bioavailability and slow onset of action. The purpose of the present study is to enhance the solubility and bioavailability of Lurasidone hydrochloride by Nanoemulsion technique. Different solubility studies were performed and the Nanoemulsion were prepared by using isopropyl myristate, Oleic acid, Capryol 90 Propylene glycol dicaprate as oil phase and selected surfactants and Co- Surfactants were used to formulate the Nanoemulsion. The formed Nanoemulsion were evaluated for different test. Based on the invitro drug release studies it is concluded the increase in the dissolution profile of the Nanoemulsion when compared to the pure API, which implies the increase in bioavailability of Lurasidone Hydrochloride, by using Capryol 90 as the oil phase, Tween 80 was used as surfactant and PEG 400 used as co-surfactant.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dcat:distribution>
      <dcat:Distribution>
        <dct:rights>
          <dct:RightsStatement rdf:about="https://creativecommons.org/licenses/by/4.0/legalcode">
            <rdfs:label>Creative Commons Attribution 4.0 International</rdfs:label>
          </dct:RightsStatement>
        </dct:rights>
        <dcat:accessURL rdf:resource="https://doi.org/10.5281/zenodo.2530509"/>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
</rdf:RDF>
158
116
views
downloads
All versions This version
Views 158158
Downloads 116116
Data volume 69.6 MB69.6 MB
Unique views 149149
Unique downloads 107107

Share

Cite as